Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells $285,236.70 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Brian Savage sold 7,342 shares of the firm’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the transaction, the insider owned 8,500 shares in the company, valued at $330,225. The trade was a 46.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Teva Pharmaceutical Industries Stock Performance

TEVA traded down $0.50 during midday trading on Tuesday, reaching $39.56. The company’s stock had a trading volume of 4,542,487 shares, compared to its average volume of 6,865,542. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. The company has a fifty day simple moving average of $35.58 and a 200 day simple moving average of $33.60. The stock has a market cap of $46.10 billion, a P/E ratio of 65.93, a PEG ratio of 4.86 and a beta of 0.87. Teva Pharmaceutical Industries Ltd. has a twelve month low of $18.21 and a twelve month high of $40.79.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The firm had revenue of $4.14 billion during the quarter. Research analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TEVA. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Teva Pharmaceutical Industries by 2.2% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock worth $1,384,216,000 after purchasing an additional 1,004,941 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock valued at $1,171,378,000 after buying an additional 5,917,423 shares in the last quarter. WCM Investment Management LLC grew its stake in Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after buying an additional 26,813,522 shares during the last quarter. Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $1,098,060,000. Finally, Geode Capital Management LLC increased its holdings in shares of Teva Pharmaceutical Industries by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 10,326,504 shares of the company’s stock worth $320,295,000 after buying an additional 336,629 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on TEVA. UBS Group raised their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, September 4th. Leerink Partners initiated coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target on the stock. Weiss Ratings downgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 8th. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Finally, Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.10.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.